vTv Therapeutics (VTVT) AI Stock Analysis

• Market Cap: $59.87M
• Dividend Yield: N/A
• Average Volume (3M): 36.30K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.89
• Revenue Growth: N/A
• EPS Growth: 65.54%
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 71
• Industry: Biotechnology
• EPS (TTM): -3.41
• Shares Outstanding: 2,612,257
• 10 Day Avg. Volume: 13,758
• 30 Day Avg. Volume: 36,303
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 53.08
• Price to Cash Flow (P/CF): -2.10
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $35.50
• Price Target Upside: 83.37% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

vTv Therapeutics' overall stock score reflects significant financial difficulties and a speculative valuation, balanced by positive developments in its clinical trials. While the corporate events suggest future potential, the current financial instability and lack of profitability weigh heavily on the stock's attractiveness.

vTv Therapeutics Business Overview & Revenue Model

Company Description

vTv Therapeutics (VTVT) is a clinical-stage biopharmaceutical company focused on the discovery and development of orally administered small molecule drug candidates. The company primarily operates in the pharmaceutical and biotechnology sectors, with a core emphasis on developing therapeutic solutions for metabolic diseases, including diabetes and inflammatory disorders. vTv Therapeutics leverages its proprietary technology platform, TTP Translational Technology, to advance its pipeline of innovative drug candidates.

How the Company Makes Money

vTv Therapeutics primarily generates revenue through partnerships and collaborations with other pharmaceutical companies. These collaborations often involve licensing agreements, wherein vTv licenses its proprietary drug candidates or technology platforms to partners in exchange for upfront payments, milestone payments based on development progress, and potential royalties on future sales. The company may also receive funding support through research grants and government incentives aimed at fostering innovation in the biopharmaceutical field. Additionally, vTv Therapeutics may engage in strategic alliances to co-develop and commercialize certain products, thereby sharing the financial risks and rewards associated with drug development.

vTv Therapeutics Financial Statement Overview

Summary

vTv Therapeutics is facing significant financial challenges with consistent operational losses, negative cash flows, and a weak balance sheet. While there is some improvement in financial stability, the overall financial health remains precarious, necessitating strategic adjustments to achieve sustainable growth and profitability.

Income Statement

vTv Therapeutics has shown unstable revenue trends with significant fluctuations over the years, highlighted by a decline in revenue in recent periods. The company exhibits negative net income consistently, leading to negative net profit margins. EBIT and EBITDA margins are also negative, indicating challenges in achieving operational profitability.

Balance Sheet

The company's balance sheet reveals high liabilities in comparison to equity, as reflected in negative stockholders' equity in multiple years, although there is some improvement in the latest year. The debt-to-equity ratio is concerning due to negative equity, posing significant financial risk. The equity ratio is negative, further emphasizing the financial instability.

Cash Flow

Operating cash flow is consistently negative, indicating ongoing cash burn. Free cash flow is also negative, suggesting insufficient cash generation to cover operating expenses. The company is reliant on financing activities for liquidity, which could be risky if external funding becomes unavailable.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.02M	0.00	2.02M	4.00M	6.41M
	Gross Profit
1.02M	-13.60M	1.93M	3.92M	-4.60M
	EBIT
-24.18M	-25.50M	-22.54M	-21.66M	-11.85M
	EBITDA
-22.52M	-25.41M	-24.77M	-17.52M	-12.02M
	Net Income Common Stockholders
-18.46M	-20.25M	-25.07M	-17.73M	-8.83M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
36.75M	9.45M	12.13M	13.41M	5.75M
	Total Assets
38.27M	11.02M	33.24M	25.47M	14.79M
	Total Debt
169.00K	529.00K	716.00K	932.00K	915.00K
	Net Debt
-36.58M	-8.92M	-11.41M	-12.48M	-4.83M
	Total Liabilities
23.96M	29.57M	43.98M	35.21M	94.89M
	Stockholders Equity
12.20M	-24.68M	-10.74M	-9.74M	-80.10M
Cash Flow		Free Cash Flow
-25.31M	-19.08M	-16.04M	-19.31M	-18.00M
	Operating Cash Flow
-25.31M	-19.08M	-16.02M	-19.31M	-18.00M
	Investing Cash Flow
0.00	4.40M	-21.00K	0.00	0.00
	Financing Cash Flow
52.61M	12.00M	14.75M	26.98M	19.47M

vTv Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 19.36
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTVT, the sentiment is Positive. The current price of 19.36 is above the 20-day moving average (MA) of 17.53, above the 50-day MA of 17.83, and above the 200-day MA of 16.08, indicating a bullish trend. The MACD of 0.22 indicates Negative momentum. The RSI at 58.20 is Neutral, neither overbought nor oversold. The STOCH value of 86.74 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VTVT.

vTv Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CORT	78 Outperform	$7.24B	55.65	23.55%	―	39.94%	32.10%
XERS	60 Neutral	$640.39M	―	222.83%	―	23.89%	16.86%
AXSM	51 Neutral	$4.78B	―	-231.63%	―	42.53%	-15.29%
Sector *	48 Neutral	$6.46B	1.17	-48.25%	2.67%	19.50%	0.61%
GERN	46 Neutral	$878.94M	―	-66.09%	―	32387.34%	15.93%
AMRN	44 Neutral	$3.83B	―	-15.79%	―	-25.86%	-37.19%
VTVT	38 Underperform	$59.87M	―	-121.97%	―	―	65.54%

vTv Therapeutics Corporate Events

vTv Therapeutics Appoints Barry Brown as Interim CFO

On April 11, 2025, vTv Therapeutics Inc. appointed Barry K. Brown as interim principal financial officer. Mr. Brown, who has been with the company since 2000, has previously served in various financial roles, including as chief accounting officer and interim principal financial officer. The company is actively searching for a permanent chief financial officer through an external process, and Mr. Brown’s appointment was made independently of any external arrangements.

Spark’s Take on VTVT Stock

According to Spark, TipRanks’ AI Analyst, VTVT is a Underperform.

vTv Therapeutics’ overall stock score reflects significant financial difficulties and a speculative valuation, balanced by positive developments in its clinical trials. While the corporate events suggest future potential, the current financial instability and lack of profitability weigh heavily on the stock’s attractiveness.

To see Spark’s full report on VTVT stock, click here.

vTv Therapeutics Resumes Phase 3 Trial for Cadisegliatin

On March 31, 2025, vTv Therapeutics announced the resumption of their Phase 3 trial for cadisegliatin, following a clinical hold lifted on March 14, 2025. The trial, aimed at developing the first oral adjunct therapy for type 1 diabetes, will now be expedited by reducing its duration from 12 to 6 months, potentially enhancing the company’s market position and offering significant benefits to stakeholders by addressing high unmet needs in diabetes management.

vTv Therapeutics CFO Steven Tuch to Resign

On February 24, 2025, vTv Therapeutics announced that Steven Tuch, its Executive Vice President and Chief Financial Officer, plans to resign effective March 21, 2025. The company is actively seeking a successor through an external search, and Mr. Tuch’s departure is not due to any disagreements with the company or its auditors.